Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Standards of diagnosis and treatment of brain tumours

2051 - Mismatch Repair deficiency (MMRD) and PD-L1 expression in High Grade Glioma (HGG) patients from Siloam Hospital Jakarta Indonesia (119O)


18 Nov 2017


Standards of diagnosis and treatment of brain tumours


Translational Research;  Central Nervous System Malignancies


Diana Patricia


Annals of Oncology (2017) 28 (suppl_10): x35-x38. 10.1093/annonc/mdx657


D. Patricia1, J. July2, E.J. Wahjoepramono2, G. Prayogi3, Z.G. Wuisan4, D. Budhiarko3, T.P. Putra3, N. Masykura3, A.R. Utomo5

Author affiliations

  • 1 Faculty Of Medicine Department Of Anatomic Pathology, Universitas Pelita Harapan, 15810 - Tangerang/ID
  • 2 Faculty Of Medicine Department Of Anatomic Neurosurgery, Universitas Pelita Harapan, 15810 - Tangerang/ID
  • 3 Cancer Diagnostics, Stem-cell and Cancer Institute, PT Kalbe Farma Tbk, 13210 - Jakarta/ID
  • 4 Institute Of Pharmaceutical Biology, Rheinische Friedrich-Wilhelms-University, D-53113 - Bonn/DE
  • 5 Cancer Diagnostics, Stem-cell and Cancer Institute & Kalbe Genomics Laboratory, PT Kalbe Farma Tbk, 13210 - Jakarta/ID


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2051


High Grade Glioma (HGG) is the most common adult CNS tumor and known by its high tumor mutation load (TML). Mismatch repair protein (MMR) is a set of proteins (namely MLH1 and MSH2) that are responsible to maintain genomic integrity. Loss of MMR expressions or Mismatch Repair Deficiency (MMRD) may lead to TML inducing production of neoantigens and iliciting cellular immune responses. Programmed death-ligand 1 (PD-L1) is widely known as co-inhibitory ligand which is responsible for immune evasion by tumor cells. The interaction among MMRD, PD-L1 and apoptotic factor, TP53, in HGG has been subjects of our investigation within patient cohort treated in Indonesian private hospital.


We performed Immunohistochemistry (IHC) assays on 43 High Grade Glioma FFPE samples from Siloam Hospital. The assay were optimized to detect MLH1, MSH2, TP53 and PD-L1 protein expression. E1L3N antibody was used to detect PD-L1 expression. MMR deficient was defined as loss of at least one of MMR proteins (MLH1, MSH) expressions. Statistical analysis were used to describe association among biomarkers as well as the age group and histological classification [Glioblastoma Multiforme (GBM) vs Other HGG (Non-GBM)].


Four sample which not qualified were omitted from analysis. MMRD were found in 33% patient (13/39) and was associated with negative expression of TP53 (p = 0.0161), suggesting TP53 independent pathway of genetic instability. PD-L1 positive rate tend to be higher in MMRD (38%) than MMR proficient (MMRP 11%) cohorts, albeit not statistically significant (p = 0.0896). There is no significant relationship between MMRD and age group as well as histological status. Overall survival analyses showed MMRD was associated with poor prognosis (p = 0.005).


MMRD may serve as useful prognostic biomarker predicting patients with poor survival. Moreover, a subset of patients with MMRD may express PD-L1 protein, a prominent predictive biomarker for immune checkpoint therapy.

Clinical trial identification

Legal entity responsible for the study

Universitas Pelita Harapan Faculty of Medicine


Kalbe Farma Tbk


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.